TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
Novo Nordisk Pharma Operations A/S
Closing information (x1000 EUR)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
14,693
|
14,532
|
28,433 |
| Earnings before taxes |
456
|
908
|
643 |
| Total assets |
11,749
|
10,449
|
18,255 |
| Current assets |
10,646
|
9,367
|
7,487 |
| Current liabilities |
5,770
|
4,751
|
4,701 |
| Equity capital |
4,185
|
3,881
|
9,643 |
| - share capital |
67
|
67
|
67 |
| Employees (average) |
0
|
0
|
0 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
35.6%
|
37.1%
|
52.8% |
| Turnover per employee | |||
| Profit as a percentage of turnover |
3.1%
|
6.2%
|
2.3% |
| Return on assets (ROA) | |||
| Current ratio |
184.5%
|
197.2%
|
159.3% |
| Return on equity (ROE) |
10.9%
|
23.4%
|
6.7% |
| Change turnover |
176
|
-13,839
|
15,170 |
| Change turnover % |
1%
|
-49%
|
114% |
| Chg. No. of employees |
0
|
0
|
0 |
| Chg. No. of employees % |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.